Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +1.28%83 Days Inventory is 209.66 as of Mar. 2026, which is 18% above its 10-year median of 178.00. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, TTY Biopharm Co ranks worse than 54.72% on this metric.
The historical rank and industry rank for TTY Biopharm Co's Days Inventory or its related term are showing as below:
ROCO:4105'
s Days Inventory Range Over the Past 10 Years
Min: 163.27 Med: 178 Max: 222.24
Current: 176.42
During the past 13 years, TTY Biopharm Co's highest Days Inventory was 222.24. The lowest was 163.27. And the median was 178.00.
ROCO:4105's Days Inventory is ranked worse than 54.72% of 921
companies
in the Drug Manufacturers industry
Industry Median: 164.68
vs ROCO:4105: 176.42
TTY Biopharm Co's Days Inventory
increased
from Mar. 2025 (196.92) to Mar. 2026 (209.66).
It might indicate that TTY Biopharm Co's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
TTY Biopharm Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TTY Biopharm Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.92.
TTY Biopharm Co (ROCO:4105) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
TTY Biopharm Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TTY Biopharm Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
TTY Biopharm Co Days Inventory Related Terms
TTY Biopharm Co Days Inventory Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a Days Inventory of 209.66 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on TTY Biopharm Co and its competitors. This is 18% above median its historical median of 178.00. Over the past decade, TTY Biopharm Co's Days Inventory has ranged from 163.27 to 222.24. According to the industry distribution chart, TTY Biopharm Co ranks #504 out of 921 companies in the Drug Manufacturers industry, placing it in the top 54.7%.
Is TTY Biopharm Co's Days Inventory too high?
TTY Biopharm Co's current Days Inventory of 209.66 is 18% above median its 10-year median of 178.00. Over the past 10 years, this metric has ranged from a low of 163.27 to a high of 222.24. The Drug Manufacturers industry median Days Inventory is 164.68. TTY Biopharm Co's value of 209.66 is 27.3% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #504 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #504 out of 921 companies for Days Inventory. This places TTY Biopharm Co in the lower half of its industry. The industry median Days Inventory is 164.68. TTY Biopharm Co's value of 209.66 is 27.3% above this benchmark. Historically, TTY Biopharm Co's own Days Inventory has ranged from 163.27 to 222.24 over the past decade. While the company's 10-year median is 178.00 vs. the industry median of 164.68, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.68, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current Days Inventory of 209.66 is 27.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current Days Inventory is 209.66, which is 18% above median its own 10-year median of 178.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.58, compared to a current price of NT$79.10 — trading 9.7% below its estimated fair value. The current Days Inventory is 209.66, which is 18% above median its 10-year median of 178.00 and 27.3% above the Drug Manufacturers industry median of 164.68. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Days Inventory is 209.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$79.10 is trading 9.7% below its estimated GF Value™ of NT$87.58.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Days Inventory: 209.66 (18% above median its 10-year median of 178.00)
GF Value™: NT$87.58 vs. price of NT$79.10 (9.7% below fair value)
Industry Position: 27.3% above the Drug Manufacturers median (#504 of 921)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
